Overview
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Background
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Indication
Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
Associated Conditions
- Intermittent Claudication
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2023/11/18 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | ||
2023/11/07 | Phase 2 | Completed | |||
2023/01/04 | Phase 2 | Active, not recruiting | |||
2022/12/02 | N/A | Active, not recruiting | |||
2022/10/27 | Not Applicable | Recruiting | |||
2022/10/26 | Phase 3 | Recruiting | |||
2022/07/20 | Phase 1 | Completed | |||
2022/03/28 | Phase 1 | Completed | |||
2022/01/14 | Phase 1 | Terminated | |||
2021/11/19 | Phase 2 | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Cilostazol Tablets | 国药准字H20243197 | 化学药品 | 片剂 | 2/20/2024 | |
| Cilostazol Tablets | 国药准字H20066511 | 化学药品 | 片剂 | 1/8/2021 | |
| Cilostazol Tablets | 国药准字H20054770 | 化学药品 | 片剂 | 4/10/2020 | |
| Cilostazol Tablets | 国药准字H20056723 | 化学药品 | 片剂 | 3/27/2020 | |
| Cilostazol Tablets | 国药准字H20074099 | 化学药品 | 片剂 | 3/21/2022 | |
| Cilostazol Tablets | 国药准字H20040579 | 化学药品 | 片剂 | 8/3/2020 | |
| Cilostazol Tablets | 国药准字H10960014 | 化学药品 | 片剂 | 2/28/2024 | |
| Cilostazol Tablets | 国药准字H20113411 | 化学药品 | 片剂 | 9/13/2021 | |
| Cilostazol Capsules | 国药准字H20080401 | 化学药品 | 胶囊剂 | 6/12/2024 | |
| Cilostazol Capsules | 国药准字H20060698 | 化学药品 | 胶囊剂 | 5/12/2021 |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||